Seelos Therapeutics (NASDAQ:SEEL) announced its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.06, Bloomberg Earnings reports.
Shares of NASDAQ SEEL traded down $0.07 during mid-day trading on Friday, reaching $1.51. The company had a trading volume of 206,865 shares, compared to its average volume of 331,921. The business has a fifty day simple moving average of $2.03. Seelos Therapeutics has a 12-month low of $1.32 and a 12-month high of $12.90.
Several brokerages have commented on SEEL. HC Wainwright began coverage on shares of Seelos Therapeutics in a report on Friday, May 10th. They issued a “buy” rating and a $4.00 target price for the company. ValuEngine upgraded shares of Seelos Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research upgraded shares of Seelos Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 27th. Finally, Roth Capital reissued a “buy” rating and issued a $8.00 price target on shares of Seelos Therapeutics in a research report on Friday.
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
Read More: Rule of 72
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.